Novo Nordisk net profit rises 8%


Novo Nordisk's (NVO) Q1 net profit increased 8% to 6.46B Danish kroner ($1.2B).

Sales +2% to 20.34B kroner, slightly missing consensus.

Excluding the impact of forex fluctuations, sales +7% in local currencies.

Novo Nordisk lowered its FY sales-growth guidance in local currencies to 7-10% from a prior forecast of 8-11%. The insulin company maintained its outlook for operating-profit growth of 10%.

Earnings were hampered by Express Scripts excluding Novo's Victoza and NovoLog diabetes treatments from its "preferred drug" list in January.

Share are -3.2% in Copenhagen. (PR)

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs